<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:25:17Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4888248" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4888248</identifier>
        <datestamp>2016-06-08</datestamp>
        <setSpec>bmcid</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id>
              <journal-title-group>
                <journal-title>BMC Infectious Diseases</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1471-2334</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4888248</article-id>
              <article-id pub-id-type="pmcid">PMC4888248</article-id>
              <article-id pub-id-type="pmc-uid">4888248</article-id>
              <article-id pub-id-type="pmid">27246604</article-id>
              <article-id pub-id-type="publisher-id">1567</article-id>
              <article-id pub-id-type="doi">10.1186/s12879-016-1567-2</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes" equal-contrib="yes">
                  <name>
                    <surname>Lamoury</surname>
                    <given-names>François M. J.</given-names>
                  </name>
                  <address>
                    <phone>+61-2-9385 0205</phone>
                    <fax>+61-2-9385 0468</fax>
                    <email>flamoury@kirby.unsw.edu.au</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1"/>
                  <xref ref-type="aff" rid="Aff6"/>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Hajarizadeh</surname>
                    <given-names>Behzad</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Keoshkerian</surname>
                    <given-names>Elizabeth</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Feld</surname>
                    <given-names>Jordan J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Amin</surname>
                    <given-names>Janaki</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Teutsch</surname>
                    <given-names>Suzy</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Matthews</surname>
                    <given-names>Gail V.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                  <xref ref-type="aff" rid="Aff4"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hellard</surname>
                    <given-names>Margaret</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dore</surname>
                    <given-names>Gregory J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                  <xref ref-type="aff" rid="Aff4"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lloyd</surname>
                    <given-names>Andrew R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2"/>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Applegate</surname>
                    <given-names>Tanya L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Grebely</surname>
                    <given-names>Jason</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <collab>on behalf of the ATAHC Study Group</collab>
                </contrib>
                <aff id="Aff1"><label/>The Kirby Institute, UNSW Australia, Sydney, Australia </aff>
                <aff id="Aff2"><label/>Inflammation and Infection Research Centre, School of Medical Sciences, UNSW Australia, Sydney, Australia </aff>
                <aff id="Aff3"><label/>Toronto Centre for Liver Disease, McLaughlin-Rotman Centre for Global Health, University of Toronto, Toronto, Canada </aff>
                <aff id="Aff4"><label/>HIV/Immunology/Infectious Diseases Clinical Services Unit, St Vincent’s Hospital, Sydney, Australia </aff>
                <aff id="Aff5"><label/>Burnet Institute, Melbourne, Australia </aff>
                <aff id="Aff6"><label/>Viral Hepatitis Clinical Research Program, The Kirby Institute, UNSW Australia, Sydney, NSW 2010 Australia </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>1</day>
                <month>6</month>
                <year>2016</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>1</day>
                <month>6</month>
                <year>2016</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2016</year>
              </pub-date>
              <volume>16</volume>
              <elocation-id>241</elocation-id>
              <history>
                <date date-type="received">
                  <day>9</day>
                  <month>11</month>
                  <year>2015</year>
                </date>
                <date date-type="accepted">
                  <day>16</day>
                  <month>5</month>
                  <year>2016</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s). 2016</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p>Human immunodeficiency virus (HIV) infection leads to more rapid progression of hepatitis C virus (HCV)-related liver fibrosis, which could be linked to differences in the severity of liver inflammation among HIV/HCV co-infected individuals compared to HCV mono-infected individuals.</p>
                  <p>This study assessed the association of HIV co-infection with pro-inflammatory and pro-fibrogenic cytokines and chemokines during recent HCV infection.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>Participants from the ATAHC study, a prospective cohort of recent HCV infection, with detectable HCV RNA at the time of acute HCV detection were included. Concentrations of 27 plasma cytokines and chemokines were measured by multiplex immunoassays and compared between those with, and without, HIV co-infection.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Out of 117 individuals with recent HCV infection included in analysis, 73 had HCV mono-infection and 44 had HIV/HCV co-infection. Individuals with HIV/HCV co-infection had significantly higher mean levels of eotaxin (1.79 vs. 1.62 log pg/mL; <italic>P</italic> &lt; 0.001), monocyte chemotactic protein 1 (MCP-1; 2.10 vs. 1.98 log pg/mL; <italic>P</italic> &lt; 0.001), and interferon-gamma inducible protein-10 (IP-10; 3.11 vs. 2.98 log pg/mL; <italic>P</italic> = 0.013). Linear regression analyses adjusting for age, alanine transaminase (ALT), HCV RNA levels, and assay run, higher eotaxin levels were independently associated with HIV/HCV co-infection (adjusted β: 0.12; 95%CI: 0.01, 0.24; <italic>P</italic> = 0.039). Higher MCP-1 levels were also independently associated with HIV/HCV co-infection in adjusted analysis (adjusted β: 0.11; 95%CI: 0.03, 0.18; <italic>P</italic> = 0.009).</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>During recent HCV, those with HIV/HCV co-infection had a stronger pro-fibrogenic mediator profile compared to those with HCV mono-infection. These findings may provide a potential explanation for accelerated liver fibrosis in HIV/HCV co-infection.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p>Australian Trial in Acute Hepatitis C (ATAHC) study was registered with ClinicalTrials.gov registry on September 11, 2005. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00192569">NCT00192569</ext-link>.</p>
                </sec>
                <sec>
                  <title>Electronic supplementary material</title>
                  <p>The online version of this article (doi:10.1186/s12879-016-1567-2) contains supplementary material, which is available to authorized users.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>HCV</kwd>
                <kwd>Cytokines</kwd>
                <kwd>Chemokines</kwd>
                <kwd>Co-infection</kwd>
                <kwd>Acute infection</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id>
                      <institution>National Health and Medical Research Council</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>510448</award-id>
                </award-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id>
                      <institution>National Institutes of Health</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>RO1 DA 15999-01</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s) 2016</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Background</title>
              <p>Among people with chronic hepatitis C virus (HCV) infection, co-infection with human immunodeficiency virus (HIV) leads to accelerated liver fibrosis progression [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR5">5</xref>]. Several mechanisms have been suggested, including increased pro-fibrogenic cytokine expression and secretion, enhanced oxidative stress, increased hepatocyte apoptosis, and immunosuppression [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR8">8</xref>], although there is no clear consensus.</p>
              <p>One potential explanation for more rapid fibrosis progression among HIV/HCV co-infected individuals compared to HCV mono-infected individuals could be differences in the severity of hepatic inflammation, leading to fibrosis. In the setting of chronic HCV infection, it has been demonstrated that individuals with HIV/HCV co-infection have higher levels of a number of pro-inflammatory cytokines and chemokines [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Further, it has been shown that intrahepatic mRNA levels of inflammatory cytokines are higher among people with HIV/HCV co-infection as compared to HCV mono-infection [<xref ref-type="bibr" rid="CR11">11</xref>]. In the setting of acute HCV infection, it has previously been demonstrated that higher levels of interferon-gamma inducible protein-10 (IP-10) levels are observed among people with HIV, compared to those without HIV infection [<xref ref-type="bibr" rid="CR12">12</xref>]. However, there are little data evaluating other cytokine and chemokine levels in people with, and without, HIV co-infection with recent HCV infection.</p>
              <p>The Australian Trial in Acute Hepatitis C (ATAHC) was a multicentre, prospective cohort study of the natural history and treatment of recent (acute and early chronic) HCV infection [<xref ref-type="bibr" rid="CR13">13</xref>]. The aim of this study was to compare cytokine and chemokine levels in people with, and without, HIV co-infection who acquired HCV infection.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods</title>
              <sec id="Sec3">
                <title>Study participants</title>
                <p>In ATAHC, acute or early chronic HCV infection was defined by an initial positive anti-HCV antibody test within 6 months of enrolment and either 1) a negative anti-HCV antibody test within 2 years prior to the initial positive anti-HCV antibody test or 2) acute clinical hepatitis within 12 months before the initial positive anti-HCV antibody result. Acute clinical infection was defined by symptomatic seroconversion illness or peak alanine transaminase (ALT) level greater than 400 IU/mL at or before the time of HCV diagnosis. In the current study, ATAHC participants with available plasma samples and HCV RNA detected at the time of acute HCV detection (screening visit) were included. Cytokines and chemokines were measured in screening visit plasma samples using a multiplex assay (see below).</p>
              </sec>
              <sec id="Sec4">
                <title>Measurement of plasma cytokines and chemokines</title>
                <p>Three human cytokine multiplex bead array assay kits utilizing technology licensed by Luminex (Bio-Rad, Gladesville, Australia) measured the following cytokines and chemokines: interleukin-1b (IL-1b), IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, interferon-gamma (IFN-g), soluble CD40 ligand (sCD40L), tumor necrosis factor alpha (TNF-a), (with Bio-Plex human TH17 15-plex), IL-2, IL-8, eotaxin-1 (or CCL11), IFN-g, interferon-gamma inducible protein-10 (IP-10, or CXCL10), monocyte chemotactic protein 1 (MCP-1, or CCL2), macrophages inflammatory proteins 1 alpha (MIP-1a, or CCL3), MIP-1ß (or CCL4), RANTES (regulated upon activation normal T-cell expressed, and presumably secreted; or CCL5) (with Bio-Plex human cytokine Group I 9-plex) and IL-18, TNF-ß, TNF-related apoptosis-inducing ligand (TRAIL, or TNFSF10) (with Bio-Plex human cytokine Group II 3-plex).</p>
                <p>The protocol was performed as per the manufacturer’s instructions and previously described [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Samples were centrifuged at 10,000 x g for 10 min at 4 °C to remove platelets and precipitates, after which the supernatants were diluted four times with assay diluents. The assay was performed using all the assay components provided in a 96-well filter plate. The raw data was analysed using the Bio-Plex Manager software, v6.1 (Bio-Rad) [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
              </sec>
              <sec id="Sec5">
                <title>Statistical analysis</title>
                <p>Log<sub>10</sub> transformed values of cytokines levels (log<sub>10</sub> pg/mL) were used in analysis given the distribution of the actual values were not normal. The mean of plasma cytokine levels were compared between individuals with and without HIV co-infection (Student <italic>T</italic> test). If the plasma cytokine level was below the level of detection, the midpoint between zero and the lowest level of reliable detection was imputed (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). Plasma levels of four cytokines (IL-23, IFN-g, TNF-b, and MIP-1a) were undetectable in ≥20 % of individuals, for which proportion of individuals with undetectable cytokine level was compared between individuals with, and without, HIV co-infection (Chi-squared test).</p>
                <p>Overall, 27 comparisons of plasma cytokines levels were conducted between two groups of individuals with, and without, HIV co-infection. Whether adjustments are needed for multiple comparisons is a matter of controversy given that multiple comparison testing might inflate type 1 error while adjustments for multiple comparisons inflate type 2 error [<xref ref-type="bibr" rid="CR17">17</xref>–<xref ref-type="bibr" rid="CR20">20</xref>]. To account for multiple comparisons, a moderately conservative significance level (<italic>alpha</italic> = 0.01) was used. In a sensitivity analysis, using Bonferroni correction for multiple comparisons, an <italic>alpha</italic> = 0.05/27 = 0.002 was also used, but the findings were similar.</p>
                <p>Two cytokines (i.e., MCP-1 and eotaxin) which had significantly different means between individuals with, and without, HIV co-infection were included in linear regression analysis. Linear regression models were fitted to assess the association of HIV co-infection with each plasma cytokine levels (log pg/mL). In the adjusted models, the association of these two cytokines and HIV co-infection was adjusted for potential confounders including age, ALT levels, and HCV RNA level at the time of acute HCV detection. Potential confounders were the variables associated with either HIV status or plasma cytokine levels in this study. To account for potential unmeasured confounders introduced by different assay runs and sample set, the models were also adjusted for assay set. All analyses were performed using Stata v12.0 (College Station, TX, United States).</p>
              </sec>
            </sec>
            <sec id="Sec6">
              <title>Results</title>
              <sec id="Sec7">
                <title>Participant characteristics</title>
                <p>A total of 117 individuals with recent HCV infection were included in the study, including 44 (38 %) with and 73 without (62 %) HIV co-infection. Background characteristics of the study population are summarized in Table <xref rid="Tab1" ref-type="table">1</xref>. All individuals with HIV co-infection were male. Compared to individuals without HIV, those with HIV co-infection were significantly older, had a higher ALT level and had a greater proportion with high HCV RNA levels (≥400,000 IU/mL) at the time of recent HCV detection (Table <xref rid="Tab1" ref-type="table">1</xref>). Two participants had HBV co-infection (positive HBsAg), both with no HIV co-infection.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics of ATAHC participants with detectable HCV RNA at the time of acute HCV detection, stratified by HIV status</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th>Total <italic>(n = 117)</italic>
</th><th>No HIV co-infection <italic>(n = 73)</italic>
</th><th>HIV co-infection <italic>(n = 44)</italic>
</th><th rowspan="2"><italic>P</italic></th></tr><tr><th>n (%) <sup>a</sup>
</th><th>n (%) <sup>a</sup>
</th><th>n (%) <sup>a</sup>
</th></tr></thead><tbody><tr><td>Sex</td><td/><td/><td/><td>&lt;0.001</td></tr><tr><td> Male</td><td>88 (75)</td><td>44 (60)</td><td>44 (100)</td><td/></tr><tr><td> Female</td><td>29 (25)</td><td>29 (40)</td><td>0 (0)</td><td/></tr><tr><td>Mean age, year (SD)</td><td>34 (10)</td><td>31 (9)</td><td>41 (8)</td><td>&lt;0.001</td></tr><tr><td>Symptomatic acute HCV</td><td/><td/><td/><td>0.825</td></tr><tr><td> No</td><td>68 (58)</td><td>43 (59)</td><td>25 (57)</td><td/></tr><tr><td> Yes</td><td>49 (42)</td><td>30 (41)</td><td>19 (43)</td><td/></tr><tr><td>ALT level at acute HCV detection, log<sub>10</sub> IU/L</td><td>2.2 (0.5)</td><td>2.1 (0.5)</td><td>2.4 (0.5)</td><td>0.006</td></tr><tr><td>Estimated duration of infection at acute HCV detection</td><td/><td/><td/><td>0.236</td></tr><tr><td>  &lt;26 weeks</td><td>69 (59)</td><td>40 (55)</td><td>29 (66)</td><td/></tr><tr><td>  ≥26 weeks</td><td>48 (41)</td><td>33 (45)</td><td>15 (34)</td><td/></tr><tr><td><italic>Interferon lambda 4</italic> genotype (rs12979860)</td><td/><td/><td/><td>0.185</td></tr><tr><td> TT/CT</td><td>56 (48)</td><td>37 (51)</td><td>19 (43)</td><td/></tr><tr><td> CC</td><td>59 (50)</td><td>37 (49)</td><td>23 (53)</td><td/></tr><tr><td> Unknown</td><td>2 (2)</td><td>0 (0)</td><td>2 (4)</td><td/></tr><tr><td>HCV RNA level at acute HCV detection</td><td/><td/><td/><td>0.031</td></tr><tr><td>  &lt;400,000 IU/mL</td><td>78 (67)</td><td>54 (74)</td><td>24 (55)</td><td/></tr><tr><td>  ≥400,000 IU/mL</td><td>39 (33)</td><td>19 (26)</td><td>20 (45)</td><td/></tr><tr><td>HCV genotype</td><td/><td/><td/><td>0.682</td></tr><tr><td> Genotype 1</td><td>67 (57)</td><td>41 (56)</td><td>26 (59)</td><td/></tr><tr><td> Genotype 3</td><td>40 (34)</td><td>27 (37)</td><td>13 (29)</td><td/></tr><tr><td> Other genotypes<sup>b</sup>
</td><td>8 (7)</td><td>4 (5)</td><td>4 (9)</td><td/></tr><tr><td> Unknown genotype</td><td>2 (2)</td><td>1 (1)</td><td>1 (2)</td><td/></tr></tbody></table><table-wrap-foot><p>Abbreviation: <italic>SD</italic> standard deviation</p><p><sup>a</sup>Percentages indicate column percentages</p><p><sup>b</sup>Including genotype 2 (<italic>n</italic> = 6), genotype 4 (<italic>n</italic> = 1) and mixed genotype (<italic>n</italic> = 1)</p></table-wrap-foot></table-wrap></p>
                <p>Among 44 individuals with HIV co-infection, 24 (55 %) had HIV viral suppression (≤50 IU/ml) at the time of recent HCV detection. Among those with no HIV viral suppression, the median HIV RNA levels at the time of recent HCV detection was 4400 IU/mL (inter quartile range: 400, 33467). CD4 count at the time of acute HCV detection was ≥500 cells/μL in 28 (64 %) individuals, and 200–499 cells/μL in 14 (32 %) individuals (not available in two individuals). Thirty-three individuals (75 %) were on antiretroviral therapy at the time of acute HCV detection, among whom, 18 (55 %) had HIV viral suppression.</p>
                <p>During the follow-up, ten individuals (9 %) cleared HCV spontaneously, while 107 individuals (91 %) either progressed to chronic infection, or received treatment.</p>
              </sec>
              <sec id="Sec8">
                <title>Distribution of cytokines levels by HIV status</title>
                <p>The distribution of cytokine levels in individuals with, and without, HIV co-infection is summarized in Table <xref rid="Tab2" ref-type="table">2</xref>. Individuals with HIV co-infection had significantly higher mean plasma levels of MCP-1 and eotaxin compared to those without HIV (<italic>P</italic> &lt; 0.001; Fig. <xref rid="Fig1" ref-type="fig">1a</xref> and <xref rid="Fig1" ref-type="fig">b</xref>). IP-10 also had higher mean plasma levels in those with HIV co-infection compared to those without HIV co-infection (<italic>P</italic> = 0.013; Fig. <xref rid="Fig1" ref-type="fig">1c</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Plasma cytokine and chemokine levels among ATAHC participants with detectable HCV RNA at the time of acute HCV detection, stratified by HIV</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Cytokine</th><th>No HIV co-infection <italic>(n = 73)</italic>
</th><th>HIV co-infection <italic>(n = 44)</italic>
</th><th><italic>P</italic></th></tr></thead><tbody><tr><td>IL-1 beta<sup>a</sup>
</td><td>0.77 (0.77)</td><td>0.56 (0.59)</td><td>0.197</td></tr><tr><td>IL-2<sup>a</sup>
</td><td>1.11 (0.12)</td><td>1.09 (0.13)</td><td>0.427</td></tr><tr><td>IL-4<sup>a</sup>
</td><td>2.16 (0.25)</td><td>2.13 (0.28)</td><td>0.589</td></tr><tr><td>IL-6<sup>a</sup>
</td><td>1.60 (0.63)</td><td>1.60 (0.64)</td><td>0.977</td></tr><tr><td>IL-8<sup>a</sup>
</td><td>1.71 (0.54)</td><td>1.71 (0.48)</td><td>0.994</td></tr><tr><td>IL-10<sup>a</sup>
</td><td>2.16 (0.66)</td><td>1.94 (0.72)</td><td>0.100</td></tr><tr><td>IL-17A<sup>a</sup>
</td><td>2.05 (0.53)</td><td>1.89 (0.70)</td><td>0.212</td></tr><tr><td>IL-17F<sup>a</sup>
</td><td>2.34 (0.49)</td><td>2.17 (0.56)</td><td>0.088</td></tr><tr><td>IL-18<sup>a</sup>
</td><td>2.44 (0.29)</td><td>2.52 (0.25)</td><td>0.171</td></tr><tr><td>IL-21<sup>a</sup>
</td><td>3.13 (0.55)</td><td>3.07 (0.56)</td><td>0.566</td></tr><tr><td>IL-22<sup>a</sup>
</td><td>1.73 (0.68)</td><td>1.81 (0.53)</td><td>0.458</td></tr><tr><td>IL-23<sup>b</sup>
</td><td>16 (22)</td><td>14 (32)</td><td>0.252</td></tr><tr><td>IL-25<sup>a</sup>
</td><td>1.46 (0.72)</td><td>1.32 (0.94)</td><td>0.415</td></tr><tr><td>IL-31<sup>a</sup>
</td><td>2.58 (0.51)</td><td>2.53 (0.61)</td><td>0.641</td></tr><tr><td>IL-33<sup>a</sup>
</td><td>3.49 (0.26)</td><td>3.41 (0.29)</td><td>0.245</td></tr><tr><td>IFN-gamma<sup>a</sup>
</td><td>2.62 (0.36)</td><td>2.68 (0.39)</td><td>0.417</td></tr><tr><td>IFN-gamma2<sup>b</sup>
</td><td>57 (79)</td><td>38 (86)</td><td>0.329</td></tr><tr><td>TNF-alpha<sup>a</sup>
</td><td>1.30 (0.47)</td><td>1.27 (0.47)</td><td>0.776</td></tr><tr><td>TNF-beta<sup>b</sup>
</td><td>68 (93)</td><td>43 (98)</td><td>0.407</td></tr><tr><td>TRAIL<sup>a</sup>
</td><td>2.07 (0.18)</td><td>2.12 (0.21)</td><td>0.119</td></tr><tr><td>sCD40L<sup>a</sup>
</td><td>2.89 (0.26)</td><td>2.90 (0.25)</td><td>0.865</td></tr><tr><td>CXCL10 (IP-10) <sup>a</sup>
</td><td>2.98 (0.24)</td><td>3.11 (0.28)</td><td>0.013</td></tr><tr><td>CCL2 (MCP-1) <sup>a</sup>
</td><td>1.98 (0.17)</td><td>2.10 (0.19)</td><td>&lt;0.001</td></tr><tr><td>CCL3 (MIP-1a) <sup>b</sup>
</td><td>36 (49)</td><td>16 (36)</td><td>0.172</td></tr><tr><td>CCL4 (MIP-1b) <sup>a</sup>
</td><td>2.62 (0.24)</td><td>2.70 (0.32)</td><td>0.158</td></tr><tr><td>CCL5 (RANTES) <sup>a</sup>
</td><td>3.78 (1.66)</td><td>3.94 (1.56)</td><td>0.606</td></tr><tr><td>CCL11 (eotaxin) <sup>a</sup>
</td><td>1.62 (0.30)</td><td>1.79 (0.21)</td><td>&lt;0.001</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> Presented as mean plasma level (standard deviation); log<sub>10</sub> pg/mL</p><p><sup>b</sup> Presented as the number with undetectable plasma level (%)</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>Distribution of MCP-1 (<bold>a</bold>), eotaxin (<bold>b</bold>) and IP-10 (<bold>c</bold>) plasma levels among ATAHC participants with detected HCV RNA at acute HCV detection, by HIV status. <italic>Horizontal lines</italic> represent the mean</p></caption><graphic xlink:href="12879_2016_1567_Fig1_HTML" id="MO1"/></fig></p>
                <p>In unadjusted linear regression analysis, HIV co-infection was significantly associated with higher plasma MCP-1 levels [log pg/mL; β (estimated mean difference): 0.13; 95 % CI: 0.06, 0.19; Table <xref rid="Tab3" ref-type="table">3</xref>]. In the adjusted model, HIV co-infection remained highly significantly associated with higher MCP-1 levels (log pg/mL; adjusted β: 0.11; 95 % CI: 0.03, 0.18; Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Unadjusted and adjusted models assessing the association of HIV co-infection with plasma MCP-1 levels (log<sub>10</sub> pg/mL) in ATAHC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Unadjusted model</th><th colspan="2">Adjusted model<sup>a</sup>
</th></tr><tr><th>Estimated mean difference<sup>b</sup> (95 % CI)</th><th><italic>P</italic></th><th>Estimated mean difference<sup>b</sup> (95 % CI)</th><th><italic>P</italic></th></tr></thead><tbody><tr><td>HIV co-infection</td><td/><td/><td/><td/></tr><tr><td> Negative</td><td>Reference</td><td/><td>Reference</td><td/></tr><tr><td> Positive</td><td>0.13 (0.06, 0.19)</td><td>&lt;0.001</td><td>0.11 (0.03, 0.18)</td><td>0.009</td></tr><tr><td>Age, 10 years</td><td>0.04 (0.00, 0.07)</td><td>0.024</td><td>0.01 (−0.03, 0.05)</td><td>0.575</td></tr><tr><td>Symptomatic acute HCV</td><td/><td/><td/><td/></tr><tr><td> No</td><td>Reference</td><td/><td/><td/></tr><tr><td> Yes</td><td>0.06 (−0.01, 0.13)</td><td>0.080</td><td/><td/></tr><tr><td>ALT level, log IU/L</td><td>0.07 (0.00, 0.14)</td><td>0.049</td><td>0.02 (−0.05, 0.10)</td><td>0.502</td></tr><tr><td>Estimated duration of infection</td><td/><td/><td/><td/></tr><tr><td>  &lt;26 weeks</td><td>Reference</td><td/><td/><td/></tr><tr><td>  ≥26 weeks</td><td>−0.05 (−0.12, 0.02)</td><td>0.196</td><td/><td/></tr><tr><td><italic>Interferon lambda rs12979860</italic> genotype</td><td/><td/><td/><td/></tr><tr><td> TT/CT</td><td>Reference</td><td/><td/><td/></tr><tr><td> CC</td><td>0.01 (−0.06, 0.08)</td><td>0.809</td><td/><td/></tr><tr><td>HCV RNA level</td><td/><td/><td/><td/></tr><tr><td>  &lt;400,000 IU/mL</td><td>Reference</td><td/><td>Reference</td><td/></tr><tr><td>  ≥400,000 IU/mL</td><td>0.05 (−0.02, 0.12)</td><td>0.181</td><td>0.02 (−0.06, 0.10)</td><td>0.623</td></tr><tr><td>HCV genotype<sup>c</sup>
</td><td/><td/><td/><td/></tr><tr><td> Genotype 1</td><td>Reference</td><td/><td/><td/></tr><tr><td> Genotype 3</td><td>0.00 (−0.07, 0.08)</td><td>0.937</td><td/><td/></tr><tr><td> Other</td><td>0.09 (−0.05, 0.23)</td><td>0.222</td><td/><td/></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Adjusted for variables associated with MCP-1 levels in unadjusted analysis or HIV status (i.e. age, ALT levels, and HCV RNA levels) as well as assay run (<italic>n</italic> = 117, <italic>R</italic>
<sup>2</sup> = 0.14)</p><p><sup>b</sup>β coefficient</p><p><sup>c</sup>Overall <italic>P =</italic> 0.467</p></table-wrap-foot></table-wrap></p>
                <p>In unadjusted linear regression analysis, HIV co-infection was also significantly associated with higher plasma eotaxin levels (log pg/mL; β: 0.17; 95 % CI: 0.07, 0.28; Table <xref rid="Tab4" ref-type="table">4</xref>). In the adjusted model, HIV co-infection remained significantly associated with higher eotaxin levels (log pg/mL; adjusted β: 0.12; 95 % CI: 0.01, 0.24; Table <xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Unadjusted and adjusted models assessing the association of HIV co-infection with plasma eotaxin levels (log<sub>10</sub> pg/mL) in ATAHC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Unadjusted model</th><th colspan="2">Adjusted model<sup>a</sup>
</th></tr><tr><th>Estimated mean difference<sup>b</sup> (95 % CI)</th><th><italic>P</italic></th><th>Estimated mean difference<sup>b</sup> (95 % CI)</th><th><italic>P</italic></th></tr></thead><tbody><tr><td>HIV co-infection</td><td/><td/><td/><td/></tr><tr><td> Negative</td><td>Reference</td><td/><td>Reference</td><td/></tr><tr><td> Positive</td><td>0.17 (0.07, 0.28)</td><td>&lt;0.001</td><td>0.12 (0.01, 0.24)</td><td>0.038</td></tr><tr><td>Age, 10 years</td><td>0.08 (0.03, 0.13)</td><td>0.001</td><td>0.06 (0.00, 0.12)</td><td>0.039</td></tr><tr><td>Symptomatic acute HCV</td><td/><td/><td/><td/></tr><tr><td> No</td><td>Reference</td><td/><td/><td/></tr><tr><td> Yes</td><td>0.05 (−0.05, 0.16)</td><td>0.309</td><td/><td/></tr><tr><td>ALT level, log IU/L</td><td>0.03 (−0.07, 0.14)</td><td>0.534</td><td>−0.02 (−0.13, 0.09)</td><td>0.712</td></tr><tr><td>Estimated duration of infection</td><td/><td/><td/><td/></tr><tr><td>  &lt;26 weeks</td><td>Reference</td><td/><td/><td/></tr><tr><td>  ≥26 weeks</td><td>−0.05 (−0.15, 0.06)</td><td>0.375</td><td/><td/></tr><tr><td><italic>Interferon lambda rs12979860</italic> genotype</td><td/><td/><td/><td/></tr><tr><td> TT/CT</td><td>Reference</td><td/><td/><td/></tr><tr><td> CC</td><td>0.05 (−0.06, 0.15)</td><td>0.379</td><td/><td/></tr><tr><td>HCV RNA level</td><td/><td/><td/><td/></tr><tr><td>  &lt;400,000 IU/mL</td><td>Reference</td><td/><td>Reference</td><td/></tr><tr><td>  ≥400,000 IU/mL</td><td>0.01 (−0.10, 0.13)</td><td>0.791</td><td>−0.02 (−0.14, 0.09)</td><td>0.689</td></tr><tr><td>HCV genotype<sup>c</sup>
</td><td/><td/><td/><td/></tr><tr><td> Genotype 1</td><td>Reference</td><td/><td/><td/></tr><tr><td> Genotype 3</td><td>−0.08 (−0.19, 0.04)</td><td>0.184</td><td/><td/></tr><tr><td> Other</td><td>0.02 (−0.19, 0.23)</td><td>0.860</td><td/><td/></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Adjusted for variables associated with eotaxin levels in unadjusted analysis or HIV status (i.e. age, ALT levels, and HCV RNA levels) as well as assay run (<italic>n</italic> = 117, <italic>R</italic>
<sup>2</sup> = 0.15)</p><p><sup>b</sup> β coefficient</p><p><sup>c</sup>Overall <italic>P =</italic> 0.372</p></table-wrap-foot></table-wrap></p>
                <p>Given that there were no females with HIV co-infection, models were not adjusted for sex. However, in a sensitivity analysis restricting the study population to males, a similar trend was observed with respect to the relationship between HIV infection and both MCP-1 (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2) and eotaxin (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3).</p>
                <p>Among individuals with HIV co-infection, the mean plasma levels of MCP-1 and exotoxin among individuals with CD4 count ≥500 cells/μL were 2.12 log pg/mL [standard deviation (SD): 0.21] and 1.78 log pg/mL (SD: 0.19), respectively, which were comparable to 2.09 log pg/mL (SD: 0.18) and 1.83 log pg/mL (SD: 0.27), respectively among those with CD4 count 200–499 cells/μL (<italic>P</italic> = 0.627 and <italic>P</italic> = 0.524, respectively).</p>
                <p>In another analysis, the association of estimated of duration of HCV infection at the time of HCV detection with plasma cytokines levels were assessed (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S4). The mean plasma levels of IL-2 was significantly higher in individuals with an estimated of duration of HCV infection ≥26 weeks (1.07 log pg/mL; SD: 0.08) compared to those with an estimated of duration of HCV infection &lt;26 weeks (1.15 log pg/mL; SD: 0.15; <italic>P</italic> = 0.001).</p>
              </sec>
            </sec>
            <sec id="Sec9">
              <title>Discussion</title>
              <p>This study assessed the association of plasma cytokine and chemokine levels with HIV co-infection among individuals with recent HCV infection. HIV/HCV co-infection was independently associated with higher plasma levels of two pro-inflammatory and pro-fibrogenic chemokines, MCP-1 and eotaxin. Increased plasma levels of MCP-1 and eotaxin in HIV/HCV co-infection might reflect increased hepatic expression of these cytokines and a subsequent chronic pro-inflammatory response [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p>
              <p>Individuals with HIV/HCV co-infection and recent HCV infection in this study had significantly higher MCP-1 plasma levels compared to those with HCV mono-infection, which is consistent with findings in the setting of chronic HCV infection [<xref ref-type="bibr" rid="CR9">9</xref>]. Similar findings in the setting of recent HCV infection are important and suggest that elevated levels of MCP-1 in HIV/HCV co-infected individuals occur early following HCV infection. A previous study has shown that MCP-1 plasma levels were elevated in HIV infection and correlated with HIV RNA levels [<xref ref-type="bibr" rid="CR23">23</xref>]. However, MCP-1 plasma levels in the current study were comparable between HIV co-infected individuals with and without HIV viral suppression.</p>
              <p>C-C chemokine receptor 2 (CCR2) and its main ligand MCP-1 (CCL2) have major roles in promoting the accumulation and activation of monocyte-macrophages in the inflamed liver, as well as the activation of hepatic stellate cells (HSC) which are key drivers of fibrosis (reviewed in [<xref ref-type="bibr" rid="CR24">24</xref>]). The role of CCR2 in promoting HSC chemotaxis and the development of hepatic fibrosis has been shown in animal models [<xref ref-type="bibr" rid="CR25">25</xref>]. In humans, increased MCP-1 expression and CCR2-dependent macrophage infiltration in the liver [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>], and also higher MCP-1 plasma levels [<xref ref-type="bibr" rid="CR28">28</xref>] have been found in the fibrotic liver. An MCP-1 gene polymorphism has been associated with increased expression of MCP-1 in the liver among individuals with chronic HCV and those with more advanced fibrosis [<xref ref-type="bibr" rid="CR29">29</xref>]. In one longitudinal study, more rapid progression of hepatic fibrosis in HCV infection was correlated with persistent and significant elevation of MCP-1 plasma levels from acute to chronic infection [<xref ref-type="bibr" rid="CR30">30</xref>]. Taken together, these data indicate the critical role of MCP-1 in development and progression of liver fibrosis. This existing evidence, coupled with our findings of increased MCP-1 plasma levels in HIV/HCV co-infection suggest a potential explanation for accelerated liver fibrosis progression in HIV/HCV co-infection, compared to HCV mono-infection. This hypothesis is supported by the in vitro data indicating that HIV can infect activated hepatic stellate cells (HSCs) to induce secretion of MCP-1 [<xref ref-type="bibr" rid="CR31">31</xref>].</p>
              <p>Knockout of CCR2 in mice results in reduced MCP-1 expression, diminished monocyte/macrophage infiltration and the development of lower levels of fibrosis following liver injury [<xref ref-type="bibr" rid="CR32">32</xref>]. Further, data from animal models indicate that inhibition of MCP-1 reduces intrahepatic macrophage accumulation and development of steatohepatitis [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Recently, Cenicriviric, a CCR2 and CCR5 antagonist, demonstrated good efficacy in suppressing HIV in phase IIb clinical trials [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. In addition to the antiretroviral effects, in animal models, Cenicriviric is anti-fibrotic, and reduces liver fibrosis progression [<xref ref-type="bibr" rid="CR36">36</xref>]. One hypothesis is that the inhibition of MCP-1 might have therapeutic potential in reducing liver fibrosis progression in individuals with HIV/HCV co-infection. This hypothesis is required to be supported by further research to evaluate the potential effect of inhibiting MCP-1 in reducing liver fibrosis.</p>
              <p>Individuals with HIV/HCV co-infection and recent HCV infection in this study also demonstrated higher plasma eotaxin levels compared to those with HCV mono-infection. Eotaxin (CCL11) is a chemokine originally known as an eosinophil-specific chemoattractant which regulates eosinophil trafficking and facilitates eosinophil migration into the tissue by activating CCR3 receptors (reviewed in [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]). Up-regulation of eotaxin expression has been demonstrated in the liver of individuals with drug-induced hepatitis and is accompanied by liver infiltration of eosinophils [<xref ref-type="bibr" rid="CR39">39</xref>]. In the setting of HCV infection, increased plasma levels of eotaxin have been demonstrated in individuals with chronic HCV infection compared with healthy controls [<xref ref-type="bibr" rid="CR40">40</xref>], while development of persistent HCV has also been found to be associated with higher plasma levels of eotaxin during acute infection [<xref ref-type="bibr" rid="CR41">41</xref>]. Moreover, eotaxin has a role in hepatic fibrogenesis. Higher plasma eotaxin levels have been identified among individuals with liver cirrhosis, with higher eotaxin levels associated with increasing stage of fibrosis, and hepatic necro-inflammation and fibrosis by liver histology [<xref ref-type="bibr" rid="CR42">42</xref>]. The observation that higher eotaxin plasma levels are observed in those with HIV/HCV co-infection suggest that, similar to MCP-1, eotaxin might have a role in explaining accelerated liver fibrosis in individuals with HIV/HCV co-infection.</p>
              <p>This study had several limitations. First, this dataset was cross-sectional, then it was not possible to measure longitudinal levels of cytokines during acute HCV infection. Further, cytokine and chemokine concentrations were measured from plasma samples, so it is possible that the levels in the blood might not reflect hepatic levels. However, it has been demonstrated that intrahepatic and peripheral sources of MCP-1 are known to both contribute to elevated serum MCP-1 concentrations [<xref ref-type="bibr" rid="CR22">22</xref>]. Data on liver fibrosis levels was not available in our participants. Further studies are needed to investigate the role of high MCP-1 and eotaxin levels in liver fibrosis progression among HIV/HCV co-infected individuals. Lastly, multiple comparison testing might inflate type 1 error in data analysis. To account for this concern, a moderately conservative significance level (<italic>alpha</italic> = 0.01) was used. We also conducted a sensitivity analysis, using Bonferroni correction for multiple comparisons (<italic>alpha</italic> = 0.05/27 = 0.002) but the findings were similar.</p>
            </sec>
            <sec id="Sec10">
              <title>Conclusion</title>
              <p>In conclusion, this study has demonstrated that compared to those without HIV infection, following acute HCV infection among people with HIV-infection, increased levels of the pro-fibrogenic chemokines, MCP-1 and eotaxin were observed. These findings could suggest a potential pathway possibly linking HIV infection with liver fibrogenesis among people with HIV/HCV infection. These findings may have also potential implications for therapeutic interventions to prevent liver fibrosis in people with HIV/HCV co-infection.</p>
            </sec>
            <sec id="Sec11">
              <title>Abbreviations</title>
              <p>ALT, alanine aminotransferase; ATAHC, Australian trial in acute hepatitis C; HCV, hepatitis C virus; IFN, interferon-gamma; IL, interleukin; IP-10, interferon-gamma inducible protein-10; IQR, inter-quartile range; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; RANTES, regulated upon activation normal T-cell expressed and presumably secreted; sCD40L, soluble CD40 ligand; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand.</p>
            </sec>
          </body>
          <back>
            <app-group>
              <app id="App1">
                <sec id="Sec12">
                  <title>Additional file</title>
                  <p>
                    <media position="anchor" xlink:href="12879_2016_1567_MOESM1_ESM.docx" id="MOESM1">
                      <label>Additional file 1:</label>
                      <caption>
                        <p><bold>Table S1.</bold> The lowest level of detection for measurement of plasma cytokine and chemokine levels. <bold>Table S2.</bold> Unadjusted and adjusted models assessing the association of HIV co-infection with plasma MCP-1 levels among males in ATAHC (<italic>n</italic>=88). <bold>Table S3.</bold> Unadjusted and adjusted models assessing the association of HIV co-infection with plasma eotaxin level among males in ATAHC (<italic>n</italic>=88). <bold>Table S4.</bold> Plasma cytokine and chemokine levels among ATAHC participants with detectable HCV RNA at the time of acute HCV detection, stratified by estimated duration of HCV infection at the time of HCV detection. (DOCX 32 kb)</p>
                      </caption>
                    </media>
                  </p>
                </sec>
              </app>
            </app-group>
            <ack>
              <title>Acknowledgements</title>
              <p>We would like to thank participants and all members of the ATAHC study group, including nurses, investigators, co-ordinators and research staff.</p>
              <sec id="FPar1">
                <title>Funding</title>
                <p>This work was supported by the National Health and Medical Research Council (NHMRC) grant HIV and HCV vaccines and immunopathogenesis (#510448) and UNSW Goldstar research grant. The ATAHC study was supported by the National Institutes of Health (#RO1 DA 15999–01). The Kirby Institute is funded by the Australian Government Department of Health and Ageing and is affiliated with the Faculty of Medicine, UNSW Australia. GD is recipient of the NHMRC practitioner fellowship. JG is recipient of the NHMRC Career Development Fellowship.</p>
              </sec>
              <sec id="FPar2">
                <title>Availability of data and materials</title>
                <p>Additional data are available as supplementary materials. All raw data are available by request to corresponding authors.</p>
              </sec>
              <sec id="FPar3">
                <title>Authors’ contributions</title>
                <p>GJD, GVM, MH, and ARL designed the original ATAHC study and wrote the protocol. BH, FMJL, JG, TLA, GJD, JJF, and ARL designed the current study. GJD, GVM, JG, BH ARL and ST provided samples and clinical data. FMJL and EK performed all laboratory work with input from TLA. BH and FMJL drafted the primary analysis plan, which was reviewed by JG, TLA, and JA. The primary analysis was conducted by BH which was reviewed by JG and JA. BH, FMJL, JG, and TLA wrote the first draft of the article. All authors contributed to and approved the final article.</p>
              </sec>
              <sec id="FPar4">
                <title>Competing interests</title>
                <p>The authors declare that they have no competing interests.</p>
              </sec>
              <sec id="FPar5">
                <title>Consent to publish</title>
                <p>Not applicable.</p>
              </sec>
              <sec id="FPar6">
                <title>Ethical approval</title>
                <p>The ATAHC protocol was reviewed and approved by Human Research Ethics Committees of St. Vincent’s Hospital, Sydney and the University Health Network, and all patients provided informed written consent. The study was registered with clinicaltrials.gov registry (NCT00192569). This study on chemokines and cytokines has been specifically approved by the St Vincent’s Hospital Human Research Ethics Committee (HREC ref#HCV12612. LNR/12/SVH/223).</p>
              </sec>
            </ack>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Di Martino</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Rufat</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Boyer</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Renard</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Degos</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Martinot-Peignoux</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study</article-title>
                  <source>Hepatology</source>
                  <year>2001</year>
                  <volume>34</volume>
                  <issue>6</issue>
                  <fpage>1193</fpage>
                  <lpage>1199</lpage>
                  <pub-id pub-id-type="doi">10.1053/jhep.2001.29201</pub-id>
                  <?supplied-pmid 11732009?>
                  <pub-id pub-id-type="pmid">11732009</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Goedert</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Eyster</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Lederman</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Mandalaki</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>De Moerloose</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>White</surname>
                      <given-names>GC</given-names>
                      <suffix>2nd</suffix>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>End-stage liver disease in persons with hemophilia and transfusion-associated infections</article-title>
                  <source>Blood</source>
                  <year>2002</year>
                  <volume>100</volume>
                  <issue>5</issue>
                  <fpage>1584</fpage>
                  <lpage>1589</lpage>
                  <?supplied-pmid 12176875?>
                  <pub-id pub-id-type="pmid">12176875</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kirk</surname>
                      <given-names>GD</given-names>
                    </name>
                    <name>
                      <surname>Mehta</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Astemborski</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Galai</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Washington</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Higgins</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study</article-title>
                  <source>Ann Intern Med</source>
                  <year>2013</year>
                  <volume>158</volume>
                  <issue>9</issue>
                  <fpage>658</fpage>
                  <lpage>666</lpage>
                  <pub-id pub-id-type="doi">10.7326/0003-4819-158-9-201305070-00604</pub-id>
                  <?supplied-pmid 23440167?>
                  <pub-id pub-id-type="pmid">23440167</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Thein</surname>
                      <given-names>HH</given-names>
                    </name>
                    <name>
                      <surname>Yi</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Dore</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Krahn</surname>
                      <given-names>MD</given-names>
                    </name>
                  </person-group>
                  <article-title>Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A meta-analysis</article-title>
                  <source>AIDS</source>
                  <year>2008</year>
                  <volume>22</volume>
                  <issue>15</issue>
                  <fpage>1979</fpage>
                  <lpage>1991</lpage>
                  <pub-id pub-id-type="doi">10.1097/QAD.0b013e32830e6d51</pub-id>
                  <?supplied-pmid 18784461?>
                  <pub-id pub-id-type="pmid">18784461</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Macías</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Berenguer</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Japón</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Girón</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Rivero</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>López-Cortés</surname>
                      <given-names>LF</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus</article-title>
                  <source>Hepatology</source>
                  <year>2009</year>
                  <volume>50</volume>
                  <issue>4</issue>
                  <fpage>1056</fpage>
                  <lpage>1063</lpage>
                  <pub-id pub-id-type="doi">10.1002/hep.23136</pub-id>
                  <?supplied-pmid 19670415?>
                  <pub-id pub-id-type="pmid">19670415</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lin</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Weinberg</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Chung</surname>
                      <given-names>RT</given-names>
                    </name>
                  </person-group>
                  <article-title>Pathogenesis of Accelerated Fibrosis in HIV/HCV Co-infection</article-title>
                  <source>J Infect Dis</source>
                  <year>2013</year>
                  <volume>207</volume>
                  <issue>suppl 1</issue>
                  <fpage>S13</fpage>
                  <lpage>S18</lpage>
                  <pub-id pub-id-type="doi">10.1093/infdis/jis926</pub-id>
                  <?supplied-pmid 23390300?>
                  <pub-id pub-id-type="pmid">23390300</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Benhamou</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Bochet</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Di Martino</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Charlotte</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Azria</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Coutellier</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group</article-title>
                  <source>Hepatology</source>
                  <year>1999</year>
                  <volume>30</volume>
                  <issue>4</issue>
                  <fpage>1054</fpage>
                  <lpage>1058</lpage>
                  <pub-id pub-id-type="doi">10.1002/hep.510300409</pub-id>
                  <?supplied-pmid 10498659?>
                  <pub-id pub-id-type="pmid">10498659</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Monto</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kakar</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Dove</surname>
                      <given-names>LM</given-names>
                    </name>
                    <name>
                      <surname>Bostrom</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Miller</surname>
                      <given-names>EL</given-names>
                    </name>
                    <name>
                      <surname>Wright</surname>
                      <given-names>TL</given-names>
                    </name>
                  </person-group>
                  <article-title>Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients</article-title>
                  <source>Am J Gastroenterol</source>
                  <year>2006</year>
                  <volume>101</volume>
                  <issue>7</issue>
                  <fpage>1509</fpage>
                  <lpage>1515</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1572-0241.2006.00613.x</pub-id>
                  <?supplied-pmid 16863554?>
                  <pub-id pub-id-type="pmid">16863554</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kushner</surname>
                      <given-names>LE</given-names>
                    </name>
                    <name>
                      <surname>Wendelboe</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Lazzeroni</surname>
                      <given-names>LC</given-names>
                    </name>
                    <name>
                      <surname>Chary</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Winters</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Osinusi</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients</article-title>
                  <source>PLoS One</source>
                  <year>2013</year>
                  <volume>8</volume>
                  <issue>4</issue>
                  <fpage>e60387</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0060387</pub-id>
                  <?supplied-pmid 23593207?>
                  <pub-id pub-id-type="pmid">23593207</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zeremski</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Dimova</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Makeyeva</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Sipley</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Jacobson</surname>
                      <given-names>IM</given-names>
                    </name>
                    <name>
                      <surname>Rennert</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients</article-title>
                  <source>J Acquir Immune Defic Syndr</source>
                  <year>2013</year>
                  <volume>63</volume>
                  <issue>1</issue>
                  <fpage>9</fpage>
                  <lpage>16</lpage>
                  <pub-id pub-id-type="doi">10.1097/QAI.0b013e31828323c1</pub-id>
                  <?supplied-pmid 23274935?>
                  <pub-id pub-id-type="pmid">23274935</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kuntzen</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Tural</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Feldmann</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Kupfer</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Nischalke</surname>
                      <given-names>HD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART</article-title>
                  <source>AIDS</source>
                  <year>2008</year>
                  <volume>22</volume>
                  <issue>2</issue>
                  <fpage>203</fpage>
                  <lpage>210</lpage>
                  <pub-id pub-id-type="doi">10.1097/QAD.0b013e3282f3553b</pub-id>
                  <?supplied-pmid 18097222?>
                  <pub-id pub-id-type="pmid">18097222</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Grebely</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Feld</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Applegate</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Matthews</surname>
                      <given-names>GV</given-names>
                    </name>
                    <name>
                      <surname>Hellard</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Sherker</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection</article-title>
                  <source>Hepatology</source>
                  <year>2013</year>
                  <volume>57</volume>
                  <issue>6</issue>
                  <fpage>2124</fpage>
                  <lpage>2134</lpage>
                  <pub-id pub-id-type="doi">10.1002/hep.26263</pub-id>
                  <?supplied-pmid 23325615?>
                  <pub-id pub-id-type="pmid">23325615</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dore</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Hellard</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Matthews</surname>
                      <given-names>GV</given-names>
                    </name>
                    <name>
                      <surname>Grebely</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Haber</surname>
                      <given-names>PS</given-names>
                    </name>
                    <name>
                      <surname>Petoumenos</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effective treatment of injecting drug users with recently acquired hepatitis C virus infection</article-title>
                  <source>Gastroenterology</source>
                  <year>2010</year>
                  <volume>138</volume>
                  <issue>1</issue>
                  <fpage>123</fpage>
                  <lpage>135</lpage>
                  <pub-id pub-id-type="doi">10.1053/j.gastro.2009.09.019</pub-id>
                  <?supplied-pmid 19782085?>
                  <pub-id pub-id-type="pmid">19782085</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>O’Connor</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Holguin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Hansen</surname>
                      <given-names>MK</given-names>
                    </name>
                    <name>
                      <surname>Maier</surname>
                      <given-names>SF</given-names>
                    </name>
                    <name>
                      <surname>Watkins</surname>
                      <given-names>LR</given-names>
                    </name>
                  </person-group>
                  <article-title>A method for measuring multiple cytokines from small samples</article-title>
                  <source>Brain Behav Immun</source>
                  <year>2004</year>
                  <volume>18</volume>
                  <issue>3</issue>
                  <fpage>274</fpage>
                  <lpage>280</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.bbi.2003.09.009</pub-id>
                  <?supplied-pmid 15050654?>
                  <pub-id pub-id-type="pmid">15050654</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Heijmans-Antonissen</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Wesseldijk</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Munnikes</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Huygen</surname>
                      <given-names>FJ</given-names>
                    </name>
                    <name>
                      <surname>van der Meijden</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Hop</surname>
                      <given-names>WC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1</article-title>
                  <source>Mediat Inflamm</source>
                  <year>2006</year>
                  <volume>2006</volume>
                  <issue>1</issue>
                  <fpage>28398</fpage>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stacey</surname>
                      <given-names>AR</given-names>
                    </name>
                    <name>
                      <surname>Norris</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Qin</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Haygreen</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Taylor</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Heitman</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Induction of a Striking Systemic Cytokine Cascade prior to Peak Viremia in Acute Human Immunodeficiency Virus Type 1 Infection, in Contrast to More Modest and Delayed Responses in Acute Hepatitis B and C Virus Infections</article-title>
                  <source>J Virol</source>
                  <year>2009</year>
                  <volume>83</volume>
                  <issue>8</issue>
                  <fpage>3719</fpage>
                  <lpage>3733</lpage>
                  <pub-id pub-id-type="doi">10.1128/JVI.01844-08</pub-id>
                  <?supplied-pmid 19176632?>
                  <pub-id pub-id-type="pmid">19176632</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <mixed-citation publication-type="other">Perneger TV. What’s wrong with Bonferroni adjustments. BMJ. 1998;316(7139):1236–8. <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1112991/pdf/1236.pdf">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1112991/pdf/1236.pdf</ext-link>.</mixed-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rothman</surname>
                      <given-names>KJ</given-names>
                    </name>
                  </person-group>
                  <article-title>No Adjustments Are Needed for Multiple Comparisons</article-title>
                  <source>Epidemiology</source>
                  <year>1990</year>
                  <volume>1</volume>
                  <issue>1</issue>
                  <fpage>43</fpage>
                  <lpage>46</lpage>
                  <pub-id pub-id-type="doi">10.1097/00001648-199001000-00010</pub-id>
                  <?supplied-pmid 2081237?>
                  <pub-id pub-id-type="pmid">2081237</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Savitz</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Olshan</surname>
                      <given-names>AF</given-names>
                    </name>
                  </person-group>
                  <article-title>Multiple Comparisons and Related Issues in the Interpretation of Epidemiologic Data</article-title>
                  <source>Am J Epidemiol</source>
                  <year>1995</year>
                  <volume>142</volume>
                  <issue>9</issue>
                  <fpage>904</fpage>
                  <lpage>908</lpage>
                  <?supplied-pmid 7572970?>
                  <pub-id pub-id-type="pmid">7572970</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Thompson</surname>
                      <given-names>JR</given-names>
                    </name>
                  </person-group>
                  <article-title>Invited Commentary: Re: ‘Multiple Comparisons and Related Issues in the Interpretation of Epidemiologic Data”</article-title>
                  <source>Am J Epidemiol</source>
                  <year>1998</year>
                  <volume>147</volume>
                  <issue>9</issue>
                  <fpage>801</fpage>
                  <lpage>806</lpage>
                  <pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a009530</pub-id>
                  <?supplied-pmid 9583708?>
                  <pub-id pub-id-type="pmid">9583708</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baeck</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Wehr</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Karlmark</surname>
                      <given-names>KR</given-names>
                    </name>
                    <name>
                      <surname>Heymann</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Vucur</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gassler</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury</article-title>
                  <source>Gut</source>
                  <year>2012</year>
                  <volume>61</volume>
                  <issue>3</issue>
                  <fpage>416</fpage>
                  <lpage>426</lpage>
                  <pub-id pub-id-type="doi">10.1136/gutjnl-2011-300304</pub-id>
                  <?supplied-pmid 21813474?>
                  <pub-id pub-id-type="pmid">21813474</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fisher</surname>
                      <given-names>NC</given-names>
                    </name>
                    <name>
                      <surname>Neil</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Williams</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Adams</surname>
                      <given-names>DH</given-names>
                    </name>
                  </person-group>
                  <article-title>Serum concentrations and peripheral secretion of the beta chemokines monocyte chemoattractant protein 1 and macrophage inflammatory protein 1alpha in alcoholic liver disease</article-title>
                  <source>Gut</source>
                  <year>1999</year>
                  <volume>45</volume>
                  <issue>3</issue>
                  <fpage>416</fpage>
                  <lpage>420</lpage>
                  <pub-id pub-id-type="doi">10.1136/gut.45.3.416</pub-id>
                  <?supplied-pmid 10446112?>
                  <pub-id pub-id-type="pmid">10446112</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Weiss</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Si-Mohamed</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Giral</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Castiel</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Ledur</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Blondin</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Plasma levels of monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1alpha and RANTES correlate with virus load in human immunodeficiency virus infection</article-title>
                  <source>J Infect Dis</source>
                  <year>1997</year>
                  <volume>176</volume>
                  <issue>6</issue>
                  <fpage>1621</fpage>
                  <lpage>1624</lpage>
                  <pub-id pub-id-type="doi">10.1086/517341</pub-id>
                  <?supplied-pmid 9395378?>
                  <pub-id pub-id-type="pmid">9395378</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tacke</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <article-title>Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liver fibrosis in vivo</article-title>
                  <source>Fibrogenesis Tissue Repair</source>
                  <year>2012</year>
                  <volume>5</volume>
                  <issue>Suppl 1</issue>
                  <fpage>S27</fpage>
                  <pub-id pub-id-type="doi">10.1186/1755-1536-5-S1-S27</pub-id>
                  <?supplied-pmid 23259611?>
                  <pub-id pub-id-type="pmid">23259611</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Seki</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>de Minicis</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Inokuchi</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Taura</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Miyai</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>van Rooijen</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>CCR2 promotes hepatic fibrosis in mice</article-title>
                  <source>Hepatology</source>
                  <year>2009</year>
                  <volume>50</volume>
                  <issue>1</issue>
                  <fpage>185</fpage>
                  <lpage>197</lpage>
                  <pub-id pub-id-type="doi">10.1002/hep.22952</pub-id>
                  <?supplied-pmid 19441102?>
                  <pub-id pub-id-type="pmid">19441102</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Marra</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>DeFranco</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Grappone</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Milani</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Pastacaldi</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Pinzani</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration</article-title>
                  <source>Am J Pathol</source>
                  <year>1998</year>
                  <volume>152</volume>
                  <issue>2</issue>
                  <fpage>423</fpage>
                  <lpage>430</lpage>
                  <?supplied-pmid 9466568?>
                  <pub-id pub-id-type="pmid">9466568</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zimmermann</surname>
                      <given-names>HW</given-names>
                    </name>
                    <name>
                      <surname>Seidler</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Nattermann</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Gassler</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Hellerbrand</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Zernecke</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Functional Contribution of Elevated Circulating and Hepatic Non-Classical CD14 &lt; sup &gt; +&lt;/sup &gt; CD16 &lt; sup &gt; +&lt;/sup &gt; Monocytes to Inflammation and Human Liver Fibrosis</article-title>
                  <source>PLoS ONE</source>
                  <year>2010</year>
                  <volume>5</volume>
                  <issue>6</issue>
                  <fpage>e11049</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0011049</pub-id>
                  <?supplied-pmid 20548789?>
                  <pub-id pub-id-type="pmid">20548789</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Marsillach</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Bertran</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Camps</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ferré</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Riu</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Tous</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The role of circulating monocyte chemoattractant protein-1 as a marker of hepatic inflammation in patients with chronic liver disease</article-title>
                  <source>Clin Biochem</source>
                  <year>2005</year>
                  <volume>38</volume>
                  <issue>12</issue>
                  <fpage>1138</fpage>
                  <lpage>1140</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.clinbiochem.2005.09.006</pub-id>
                  <?supplied-pmid 16242682?>
                  <pub-id pub-id-type="pmid">16242682</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mühlbauer</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bosserhoff</surname>
                      <given-names>AK</given-names>
                    </name>
                    <name>
                      <surname>Hartmann</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Thasler</surname>
                      <given-names>WE</given-names>
                    </name>
                    <name>
                      <surname>Weiss</surname>
                      <given-names>TS</given-names>
                    </name>
                    <name>
                      <surname>Herfarth</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease</article-title>
                  <source>Gastroenterology</source>
                  <year>2003</year>
                  <volume>125</volume>
                  <issue>4</issue>
                  <fpage>1085</fpage>
                  <lpage>1093</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0016-5085(03)01213-7</pub-id>
                  <?supplied-pmid 14517792?>
                  <pub-id pub-id-type="pmid">14517792</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Farci</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Wollenberg</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Diaz</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Engle</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Lai</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Klenerman</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis</article-title>
                  <source>Proc Natl Acad Sci</source>
                  <year>2012</year>
                  <volume>109</volume>
                  <issue>36</issue>
                  <fpage>14562</fpage>
                  <lpage>14567</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.1210592109</pub-id>
                  <?supplied-pmid 22829669?>
                  <pub-id pub-id-type="pmid">22829669</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tuyama</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Hong</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Saiman</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Ozkok</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Mosoian</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: Implications for the pathogenesis of HIV/hepatitis C virus–induced liver fibrosis</article-title>
                  <source>Hepatology</source>
                  <year>2010</year>
                  <volume>52</volume>
                  <issue>2</issue>
                  <fpage>612</fpage>
                  <lpage>622</lpage>
                  <pub-id pub-id-type="doi">10.1002/hep.23679</pub-id>
                  <?supplied-pmid 20683959?>
                  <pub-id pub-id-type="pmid">20683959</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mitchell</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Couton</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Couty</surname>
                      <given-names>J-P</given-names>
                    </name>
                    <name>
                      <surname>Anson</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Crain</surname>
                      <given-names>A-M</given-names>
                    </name>
                    <name>
                      <surname>Bizet</surname>
                      <given-names>V</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Dual Role of CCR2 in the Constitution and the Resolution of Liver Fibrosis in Mice</article-title>
                  <source>Am J Pathol</source>
                  <year>2009</year>
                  <volume>174</volume>
                  <issue>5</issue>
                  <fpage>1766</fpage>
                  <lpage>1775</lpage>
                  <pub-id pub-id-type="doi">10.2353/ajpath.2009.080632</pub-id>
                  <?supplied-pmid 19359521?>
                  <pub-id pub-id-type="pmid">19359521</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Parker</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Walters</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ertl</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Ebsworth</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Tan</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>McMahon</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis</article-title>
                  <source>Lancet</source>
                  <year>2014</year>
                  <volume>383</volume>
                  <fpage>S78</fpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(14)60341-X</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gathe</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Cade</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>De Jesus</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <source>Week-24 primary analysis of cenicriviroc vs efavirenz, in combination with emtricitabine/tenofovir, in treatment-naive HIV-1+ adults with CCR5-tropic virus</source>
                  <year>2013</year>
                  <publisher-loc>Atlanta</publisher-loc>
                  <publisher-name>The 20th Conference on Retroviruses and Opportunistic Infections</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Feinberg</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Thompson</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Cade</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <source>Final week 48 analysis of cenicriviroc compared to efavirenz in combination with emtricitabine/tenofovir in treatment-naïve HIV-1-infected adults with CCR5-tropic virus</source>
                  <year>2013</year>
                  <publisher-loc>Brussels</publisher-loc>
                  <publisher-name>The 14th EACS</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hong</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Chou</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Friedman</surname>
                      <given-names>SL</given-names>
                    </name>
                  </person-group>
                  <article-title>Significant anti-fibrotic activity of cenicriviroc, a dual CCR2/CCR5 antagonist in a rat model of thioacetamide-induced liver fibrosis and cirrhosis</article-title>
                  <source>Hepatology</source>
                  <year>2013</year>
                  <volume>58</volume>
                  <issue>6</issue>
                  <fpage>1381A</fpage>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Broide</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Sriramarao</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Eosinophil trafficking to sites of allergic inflammation</article-title>
                  <source>Immunol Rev</source>
                  <year>2001</year>
                  <volume>179</volume>
                  <issue>1</issue>
                  <fpage>163</fpage>
                  <lpage>172</lpage>
                  <pub-id pub-id-type="doi">10.1034/j.1600-065X.2001.790116.x</pub-id>
                  <?supplied-pmid 11292020?>
                  <pub-id pub-id-type="pmid">11292020</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lampinen</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Carlson</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Håkansson</surname>
                      <given-names>LD</given-names>
                    </name>
                    <name>
                      <surname>Venge</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Cytokine-regulated accumulation of eosinophils in inflammatory disease</article-title>
                  <source>Allergy</source>
                  <year>2004</year>
                  <volume>59</volume>
                  <issue>8</issue>
                  <fpage>793</fpage>
                  <lpage>805</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1398-9995.2004.00469.x</pub-id>
                  <?supplied-pmid 15230810?>
                  <pub-id pub-id-type="pmid">15230810</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pham</surname>
                      <given-names>B-N</given-names>
                    </name>
                    <name>
                      <surname>Bernuau</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Durand</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Sauvanet</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Degott</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Prin</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease</article-title>
                  <source>J Hepatol</source>
                  <year>2001</year>
                  <volume>34</volume>
                  <issue>4</issue>
                  <fpage>537</fpage>
                  <lpage>547</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0168-8278(00)00057-X</pub-id>
                  <?supplied-pmid 11394653?>
                  <pub-id pub-id-type="pmid">11394653</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yoneda</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Umemura</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Joshita</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ichijo</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Matsumoto</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Yoshizawa</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C</article-title>
                  <source>Hepatol Res</source>
                  <year>2011</year>
                  <volume>41</volume>
                  <issue>6</issue>
                  <fpage>587</fpage>
                  <lpage>593</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1872-034X.2011.00802.x</pub-id>
                  <?supplied-pmid 21504519?>
                  <pub-id pub-id-type="pmid">21504519</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Osburn</surname>
                      <given-names>WO</given-names>
                    </name>
                    <name>
                      <surname>Levine</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Chattergoon</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Thomas</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Cox</surname>
                      <given-names>AL</given-names>
                    </name>
                  </person-group>
                  <article-title>Anti-inflammatory cytokines, pro-fibrogenic chemokines and persistence of acute HCV infection</article-title>
                  <source>J Viral Hepat</source>
                  <year>2013</year>
                  <volume>20</volume>
                  <issue>6</issue>
                  <fpage>404</fpage>
                  <lpage>413</lpage>
                  <pub-id pub-id-type="doi">10.1111/jvh.12052</pub-id>
                  <?supplied-pmid 23647957?>
                  <pub-id pub-id-type="pmid">23647957</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tacke</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Trautwein</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Yagmur</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Hellerbrand</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Wiest</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Brenner</surname>
                      <given-names>DA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course</article-title>
                  <source>J Gastroenterol Hepatol</source>
                  <year>2007</year>
                  <volume>22</volume>
                  <issue>8</issue>
                  <fpage>1256</fpage>
                  <lpage>1264</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1440-1746.2006.04621.x</pub-id>
                  <?supplied-pmid 17688666?>
                  <pub-id pub-id-type="pmid">17688666</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
